Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston, Robert Lowsky, Judith Shizuru, Everett Meyer, Lori Muffly, Andrew R Rezvani, Parveen Shiraz, Surbhi Sidana, Saurabh Dahiya, David B Miklos, Robert S Negrin, Wen-Kai Weng
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post-AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow-up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse...
April 25, 2024: American Journal of Hematology